GEN News Highlights

SuperNova Inks Deal with KSB to Expand Diagnostic Business into China

(Page
1
of
1)

SuperNova Diagnostics® will expand into China under an agreement with in vitro diagnostic kit maker Shenzhen Kang Sheng Bao Bio-Technology (KSB). "This collaborative relationship allows SuperNova and KSB to expand R&D, manufacturing, and commercialization into one of the world's largest markets," points out Neil Campbell, president and CEO of SuperNova Diagnostics.

KSB specializes in research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and affiliated markets. SuperNova focuses on detecting pathogens that lead to enteric and diarrheal diseases, malaria, tuberculosis, influenza, and other infectious diseases for humans. It also develops diagnostics for food and water safety as well as animal health.

SuperNova’s lead technology, AmpCrystal®, consists of hyper-dense, energy-mediated nanocrystals designed to let individuals without CLIA training test for a range of protein analytes and directly detect unamplified DNA in humans, animals, or environmental samples. The company says that the technology promises results in minutes.

AmpCrystal is used in multiple diagnostic formats including lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products, and OEM. It can reportedly be integrated into current diagnostic formats.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.